Development
BioRay moves dual-payload TROP2 ADC into the clinic
China-based BioRay Pharmaceutical Co., Ltd. has registered a first-in-human Phase I study of BR113, a dual-payload antibody-drug conjugate (ADC) targeting...
Laekna takes aim at Truqap as China accepts afuresertib NDA
China's drug regulator has accepted a new drug application for afuresertib, the pan-AKT inhibitor developed by Shanghai-based Laekna (HKEX: 2105.HK),...
Keymed/Belenos’s twice-yearly TSLP × IL-13 bispecific clears Phase II
China-based Keymed Biosciences Inc. (HKEX: 02162) announced that its Phase II clinical trial of CM512, a recombinant bispecific antibody targeting both...
MoonLake's sonelokimab meets all endpoints in Phase III psoriatic arthritis trial
MoonLake Immunotherapeutics (Nasdaq: MLTX) reported positive Week 16 topline results from the Phase III IZAR-1 trial of sonelokimab in biologic-naïve...
Silence's divesiran achieves 88% response in Phase II PV trial with quarterly dosing
Silence Therapeutics plc (Nasdaq: SLN) reported positive topline results from the Phase II SANRECO trial of divesiran in polycythemia vera (PV) on August...
AbCellera's NK3R antibody meets both endpoints in Phase II menopause study
AbCellera Biologics (Nasdaq: ABCL) reported that ABCL635, its investigational neurokinin 3 receptor (NK3R) antagonist antibody, met both primary efficacy...
Sionna's lead cystic fibrosis program fails Phase IIa test, clouding NBD1 stabilizer strategy
Sionna Therapeutics (Nasdaq: SION) reported on August 10 that its lead cystic fibrosis program has failed its first test in patients, forcing a strategic...
Tenax’s levosimendan fails Phase III LEVEL trial in PH-HFpEF
Tenax Therapeutics (Nasdaq: TENX) reported on August 10 that the Phase III LEVEL trial of levosimendan — a calcium sensitizer and ATP-sensitive potassium...
Luzhu’s LZ901 shingles vaccine Phase III results published in Nature Communications
Beijing Luzhu Biotechnology Co., Ltd. (HKEX: 02480) announced on August 9 that Phase III clinical trial results for its recombinant herpes zoster vaccine...
Genfleet becomes first to test oral KRAS G12D inhibitor in Phase III for NSCLC
China-based GenFleet Therapeutics (Shanghai) Inc. (HKEX: 02595) announced on August 10 that the first patient has been dosed in Kylin-Flight 01, a...
Neurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study
Neurocrine Biosciences (Nasdaq: NBIX) has dosed the first participants in a Phase I first-in-human study of NBIP-1968, an internally discovered...
Dispatch advances synthetic-antigen CAR T platform into first-in-human testing
Dispatch Bio has dosed the first patient in a Phase I study of DISP-10 immunotherapy, a combination approach pairing a tumor-specific virus with an approved...
Vistagen reports exploratory Phase II miss for social anxiety drug candidate
South San Francisco-based Vistagen Therapeutics (Nasdaq: VTGN) reported topline results on August 6 from an exploratory Phase II study of fasedienol nasal...
Edding Genor tries trispecific PD-1/CTLA-4/VEGF antibody against breast cancer
Hong Kong-listed Edding Genor Group Holdings Limited (HKEX: 06998) announced on August 6 that the first subject has been dosed in the Phase Ib/II clinical...
Mediar partners with Ono Pharma on fibro-inflammatory discovery
Boston-based Mediar Therapeutics has entered a collaboration and option agreement with Japan-based Ono Pharmaceutical to develop antibody therapies for...
The AllSci Brief
Free, systematic R&D and deal news. Daily.